All In Biotech

Drug Trial Radar · NCT02134834

A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of OP0595 Administered Intravenously in Healthy Male Subjects.

Last checked: Nov 19, 2026Latest source record: Dec 12, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 2014

Primary completion

Aug 2014

Study completion Nov 2014

Sponsor

Lead sponsor
Meiji Seika Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this study are to assess the safety, tolerability and pharmacokinetic profile of OP0595 administered intravenously to healthy male, Caucasian, adult subjects at single escalating doses.

Conditions

  • Healthy Volunteers
  • Bacterial Infections

Interventions

  • OP0595Drug

    Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

  • PlaceboDrug

    Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety from baseline through the end of the studyTime frame: Day 1 to Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.